InnoCare Pharma announced its 2025 results, achieving its first full-year profitability with a 135.3% revenue increase to RMB 2,375 million, driven by strong commercial growth and strategic licensing deals. The company secured two new drug approvals, expanded its global presence through major out-licensing agreements, and advanced multiple clinical trials, especially in cancer and autoimmune diseases. With a strong cash position and increased R&D investment, InnoCare aims to accelerate drug approvals and global development in 2026, focusing on innovative therapies for hemato-oncology and autoimmune diseases. This milestone marks a significant step in its 10-year growth and 2.0 development strategy.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
